Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal Study of Iodine I-131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lym-phomas[J]. J Clin Oncol, 2001, 19: 3 908 -3 911.
[2]
Knapp FF Jr, Beets AL, Guhlke S, et al. Availability of Rhenium-188 From the Alumina-based Tungsten-188/Rhenium-188 Generator for Preparation of Rhenium-188-Labeled Radiopharma-ceuticals for Cancer Treatment [J]. Anticancer Res, 1997, 17: 1783 - 1796.
[3]
Vose JM, Wahl RL, Saleh M, et al. Muticenter Phase Ⅱ Study of Iodine I-131 Tositumomab for Chemotherapy-relapsed/refractory Low-grade and Transformed Low-grade B-cell Non-Hodgkin's Lymphomas[J]. J Clin Oncol, 2000, 18:1316 -1323.
[4]
Knapp FF Jr, Callahan AP, Beets AL, et al. P-rocessing of Reactor-produced 188 W for Fabrication of Clinical Scale Alumina-based 188W-188ReGenerators [J]. Appl Radiat Isot, 1994, 45(12): 1123-1128.
[5]
Knapp FF Jr, Mirzadeh S Jr. The Continuing Important Role of Radionuclide Generator System for Nuclear Medicine[J]. Eur J Nucl Med, 1994, 20(12): 1151-1165.
Callahan AP, Rice DE, Mcpherson DW, et al. The Use of Alumina " SepPaks" as a Simple Method for the Removal and Determination of Tungsten-188 Breakthrough From Tungsten-188/Rhenium-188Generators [J]. Appl Radiat Isot, 1992, 43(6):801-804.
[13]
Wahl RL, Zasadny KR, Estes J, et al. Single Center Experience With Iodine I131 Tositumomab Radioimmunotherapy for Previously Untreated Follicular Lymphoma (FL ) [J]. J Nucl Med, 2000, 41 (suppl):79.
